When, how fast and which way: from phenoconversion to personalized progression in synucleinopathy.

Abstract

This scientific commentary refers to ‘Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum’ by Roascio et al.  (https://doi.org/10.1093/brain/awag193).